BRAF (K601E)

BRAF · Variant type: point · HGVS: p.K601E

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ripretinib	99.5%	0.5%	92.95
2	Encorafenib	98.8%	1.2%	98.50
3	Dabrafenib	98.8%	1.2%	94.74
4	Regorafenib	97.1%	2.9%	95.99
5	Sorafenib	96.6%	3.4%	96.72
6	Ponatinib	96.4%	3.6%	78.23
7	Vemurafenib	91.2%	8.8%	96.49
8	Dasatinib	88.8%	11.2%	87.97
9	Apatinib	88.4%	11.6%	97.73
10	Nilotinib	87.6%	12.4%	96.49
11	Erdafitinib	80.4%	19.6%	95.71
12	Umbralisib	78.3%	21.7%	98.74
13	Pazopanib	68.0%	32.0%	97.49
14	Upadacitinib	54.0%	46.0%	97.98
15	Rabusertib	48.6%	51.4%	98.74
16	Imatinib	41.3%	58.7%	99.00
17	Dacomitinib	37.8%	62.2%	97.99
18	Osimertinib	36.7%	63.3%	97.24
19	Gedatolisib	35.6%	64.4%	99.75
20	Pacritinib	35.2%	64.8%	88.64
21	Tivozanib	30.9%	69.1%	92.42
22	Canertinib	28.1%	71.9%	96.49
23	Trametinib	27.7%	72.3%	99.50
24	Fostamatinib	25.6%	74.4%	96.74
25	Ribociclib	21.7%	78.3%	99.25

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ripretinib	99.5%	100.0%	-0.5%
Encorafenib	98.8%	98.0%	+0.8%
Dabrafenib	98.8%	98.3%	+0.4%
Regorafenib	97.1%	98.3%	-1.2%
Sorafenib	96.6%	98.5%	-1.9%
Ponatinib	96.4%	99.4%	-3.0%
Vemurafenib	91.2%	92.8%	-1.6%
Dasatinib	88.8%	80.6%	+8.2%
Apatinib	88.4%	94.1%	-5.7%
Nilotinib	87.6%	85.8%	+1.8%
Erdafitinib	80.4%	54.1%	+26.3%
Umbralisib	78.3%	65.3%	+13.0%
Pazopanib	68.0%	79.3%	-11.3%
Upadacitinib	54.0%	49.6%	+4.4%
Rabusertib	48.6%	41.1%	+7.6%
Imatinib	41.3%	—	—
Dacomitinib	37.8%	46.6%	-8.8%
Osimertinib	36.7%	—	—
Gedatolisib	35.6%	56.5%	-20.9%
Pacritinib	35.2%	58.5%	-23.3%
Tivozanib	30.9%	41.8%	-10.9%
Canertinib	28.1%	40.7%	-12.6%
Trametinib	27.7%	—	—
Fostamatinib	25.6%	—	—
Ribociclib	21.7%	—	—

Cancer	Organ	Source
glioma_central_nervous_system	Brain/CNS	ref
carcinoma_thyroid	Thyroid	ref
lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue	Blood/Lymphatic System	ref
carcinoma_prostate	Prostate	ref
carcinoma_lung	Lung	ref
carcinoma_large_intestine	Large Intestine	ref
malignant_melanoma_NS	Other	ref
malignant_melanoma_skin	Skin	ref
benign_melanocytic_nevus_skin	Skin	ref
carcinoma_salivary_gland	Salivary Gland	ref
carcinoma_endometrium	Uterus	ref
adenoma-nodule-goitre_thyroid	Thyroid	ref
germ_cell_tumour_ovary	Ovary	ref
other_pancreas	Pancreas	ref
other_upper_aerodigestive_tract	Brain/CNS	ref
adenoma_large_intestine	Large Intestine	ref
carcinoma_biliary_tract	Biliary Tract	ref
adnexal_tumour_skin	Skin	ref
adenoma_small_intestine	Small Intestine	ref
carcinoma_stomach	Stomach/Digestive Tract	ref
carcinoma_breast	Breast	ref
carcinoma_kidney	Kidney	ref
serrated_polyp_large_intestine	Large Intestine	ref
mesothelioma_pleura	Lung	ref
carcinoma_in_situ_breast	Breast	ref
leiomyosarcoma_soft_tissue	Soft Tissue	ref
CLLE-ES	Blood/Lymphatic System	ref
DLBC-US	Blood/Lymphatic System	ref
MELA-AU	Skin	ref
PRAD-CA	Prostate	ref
PRAD-US	Prostate	ref
SKCM-US	Skin	ref
STAD-US	Stomach/Digestive Tract	ref
THCA-US	Thyroid	ref
UCEC-US	Uterus	ref
DLBC	Blood/Lymphatic System	ref
PRAD	Prostate	ref
SKCM	Skin	ref
STAD	Stomach/Digestive Tract	ref
THCA	Thyroid	ref
UCEC	Uterus	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 31.1ms